Compare CRNC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | CAPR |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.2M | 324.6M |
| IPO Year | N/A | N/A |
| Metric | CRNC | CAPR |
|---|---|---|
| Price | $11.33 | $29.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $11.50 | ★ $41.38 |
| AVG Volume (30 Days) | 1.0M | ★ 5.4M |
| Earning Date | 02-05-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | $11,130,509.00 |
| Revenue This Year | $27.55 | N/A |
| Revenue Next Year | N/A | $16,329.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.94 | $4.30 |
| 52 Week High | $27.50 | $40.37 |
| Indicator | CRNC | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 73.78 |
| Support Level | $10.87 | $25.60 |
| Resistance Level | $11.65 | $30.00 |
| Average True Range (ATR) | 0.57 | 1.92 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 29.23 | 69.91 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.